-
Sector Analysis
NewCloud Communications Market Opportunity Forecasts by Geography, Technology Segments and Industry Verticals to 2027
Cloud Communications Market Report Overview The Cloud Communications market was valued at US$ 78.00 billion in 2022 and will grow at a compounded annual growth rate (CAGR) of 18.30% to reach a value of US$ 180.70 billion by 2027. The cumulative revenue generation opportunities for Cloud Communications providers is estimated at US$ 732.90 billion between 2022 to 2027. Cloud Communications Market Outlook, 2022-2027 (in US$ Billion) For more insights into the Cloud Communications market forecast Download a free report sample...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Nemonoxacin in Community Acquired Pneumonia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Nemonoxacin in Community Acquired Pneumonia Drug Details: Nemonoxacin (Taigexyn, Wingard) is a non-fluorinated quinolone antibiotic. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Anakinra in Community Acquired Pneumonia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Anakinra in Community Acquired Pneumonia Drug Details: Anakinra (Kineret) is an immunosuppressant produced in Escherichia...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BT-588 in Community Acquired Pneumonia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BT-588 in Community Acquired Pneumonia Drug Details: BT-588 (IgM concentrate) is under development as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SR-1375 in Community Acquired Pneumonia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SR-1375 in Community Acquired Pneumonia Drug Details: SR-1375 is under development for the treatment...
-
Product Insights
New
